A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)
Latest Information Update: 16 Jan 2024
At a glance
- Drugs Zilovertamab vedotin (Primary)
- Indications Acute myeloid leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Richter's syndrome; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Acronyms waveLINE-001
- Sponsors VelosBio
- 11 Jan 2024 Status changed from active, no longer recruiting to completed.
- 04 Dec 2023 Planned End Date changed from 30 Oct 2023 to 18 Dec 2023.
- 04 Dec 2023 Planned primary completion date changed from 1 Sep 2023 to 18 Dec 2023.